The present application is directed to compounds that are TRPV1 antagonists and have formula wherein variables Ar1, L1, R1, R2, R3, R4, R5, Y1, Y2, and Y3, are as defined in the description, which are useful for treating disorders caused by or exacerbated by vanilloid receptor activity. The level of CCR4, CCL17 and CCL22 are found to increase during malignant tumor progression. Further, when a resin material of the space keeping members is soft, reinforcing members, which have electrical insulation and are hardly deformed in a thermocompression bonding, are dispersed into the resin material, so that the space keeping ability is fully exhibited.